Jane Street’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.64M | Sell |
173,743
-847,756
| -83% | -$19.1M | ﹤0.01% | 4004 |
|
|
2025
Q4 | $23.5M | Buy |
1,021,499
+667,331
| +188% | +$21.9M | ﹤0.01% | 1480 |
|
|
2025
Q3 | $10.7M | Buy |
354,168
+242,442
| +217% | +$7.27M | ﹤0.01% | 2337 |
|
|
2025
Q2 | $4.06M | Sell |
111,726
-53,921
| -33% | -$1.94M | ﹤0.01% | 3303 |
|
|
2025
Q1 | $6M | Buy |
165,647
+84,132
| +103% | +$3.5M | ﹤0.01% | 2663 |
|
|
2024
Q4 | $3.43M | Sell |
81,515
-49,926
| -38% | -$2.48M | ﹤0.01% | 3219 |
|
|
2024
Q3 | $7.3M | Sell |
131,441
-53,620
| -29% | -$2.73M | ﹤0.01% | 2302 |
|
|
2024
Q2 | $7.61M | Buy |
185,061
+119,623
| +183% | +$5.11M | ﹤0.01% | 2365 |
|
|
2024
Q1 | $3.06M | Sell |
65,438
-55,277
| -46% | -$2.61M | ﹤0.01% | 3378 |
|
|
2023
Q4 | $5.77M | Buy |
120,715
+91,065
| +307% | +$3.53M | ﹤0.01% | 2650 |
|
|
2023
Q3 | $1.06M | Sell |
29,650
-47,977
| -62% | -$1.9M | ﹤0.01% | 5100 |
|
|
2023
Q2 | $3.58M | Buy |
77,627
+48,854
| +170% | +$2.27M | ﹤0.01% | 3219 |
|
|
2023
Q1 | $1.15M | Sell |
28,773
-2,090
| -7% | -$89.7K | ﹤0.01% | 4749 |
|
|
2022
Q4 | $1.43M | Sell |
30,863
-4,137
| -12% | -$163K | ﹤0.01% | 4412 |
|
|
2022
Q3 | $1.45M | Buy |
35,000
+23,861
| +214% | +$1.23M | ﹤0.01% | 4739 |
|
|
2022
Q2 | $664K | Buy |
11,139
+8,248
| +285% | +$508K | ﹤0.01% | 6232 |
|
|
2022
Q1 | $210K | Sell |
2,891
-25,117
| -90% | -$1.75M | ﹤0.01% | 8974 |
|
|
2021
Q4 | $2.36M | Sell |
28,008
-3,393
| -11% | -$276K | ﹤0.01% | 4153 |
|
|
2021
Q3 | $2.83M | Sell |
31,401
-35,422
| -53% | -$3.2M | ﹤0.01% | 3771 |
|
|
2021
Q2 | $6.37M | Buy |
66,823
+61,250
| +1,099% | +$6.38M | ﹤0.01% | 2290 |
|
|
2021
Q1 | $635K | Sell |
5,573
-27,791
| -83% | -$3.78M | ﹤0.01% | 6360 |
|
|
2020
Q4 | $4.62M | Buy |
33,364
+12,467
| +60% | +$1.48M | ﹤0.01% | 2232 |
|
|
2020
Q3 | $1.72M | Sell |
20,897
-1,391
| -6% | -$115K | ﹤0.01% | 3275 |
|
|
2020
Q2 | $1.74M | Buy |
+22,288
| New | +$1.48M | ﹤0.01% | 3255 |
|
|
2020
Q1 | – | Sell |
-19,651
| Closed | -$839K | – | 5854 |
|
|
2019
Q4 | $839K | Buy |
19,651
+9,266
| +89% | +$382K | ﹤0.01% | 3002 |
|
|
2019
Q3 | $444K | Buy |
+10,385
| New | +$564K | ﹤0.01% | 3688 |
|
|
2018
Q4 | – | Sell |
-25,602
| Closed | -$1.95M | – | 5558 |
|
|
2018
Q3 | $1.95M | Buy |
+25,602
| New | +$2.08M | ﹤0.01% | 1930 |
|
|
2018
Q2 | – | Sell |
-6,652
| Closed | -$339K | – | 5494 |
|
|
2018
Q1 | $339K | Sell |
6,652
-2,169
| -25% | -$109K | ﹤0.01% | 3888 |
|
|
2017
Q4 | $409K | Buy |
8,821
+1,828
| +26% | +$89.6K | ﹤0.01% | 3406 |
|
|
2017
Q3 | $372K | Buy |
+6,993
| New | +$414K | ﹤0.01% | 3447 |
|
|
2016
Q2 | – | Sell |
-6,505
| Closed | -$412K | – | 4494 |
|
|
2016
Q1 | $412K | Buy |
6,505
+524
| +9% | +$34.3K | ﹤0.01% | 2813 |
|
|
2015
Q4 | $671K | Buy |
+5,981
| New | +$598K | ﹤0.01% | 2163 |
|
|
2015
Q3 | – | Sell |
-8,211
| Closed | -$841K | – | 4053 |
|
|
2015
Q2 | $841K | Buy |
+8,211
| New | +$638K | 0.01% | 1729 |
|
Other funds holding RARE
VPM
VCM
RI
SI
BG
Jane Street's RARE Position: Q1 2026 in Review
Jane Street reduced its Ultragenyx Pharmaceutical (RARE) stake by 83% in Q1 2026, selling an estimated $19.1M and leaving 173,743 shares worth $3.64M. The position accounts for ﹤0.01% of the portfolio, ranked #4004.
Jane Street first reported a position in RARE in Q2 2015 and has held it in 33 quarters since. The position peaked at $23.5M in Q4 2025. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.
- Jane Street held 173,743 shares of Ultragenyx Pharmaceutical worth $3.64M as of Q1 2026.
- Jane Street sold 847,756 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $19.1M.
- Ultragenyx Pharmaceutical made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #4004 holding.
- Jane Street first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and has held it in 33 quarters since.
- Jane Street's Ultragenyx Pharmaceutical position peaked at $23.5M in Q4 2025.
- 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.